Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(3): 419-423
Yang Zhou, Fu Binsheng. Research status of liver transplantation in the treatment of non-alcoholic fatty liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 419-423. doi: 10.3969/j.issn.1674-7445.2020.03.017
Citation: Yang Zhou, Fu Binsheng. Research status of liver transplantation in the treatment of non-alcoholic fatty liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 419-423. doi: 10.3969/j.issn.1674-7445.2020.03.017
shu

Research status of liver transplantation in the treatment of non-alcoholic fatty liver disease

doi: 10.3969/j.issn.1674-7445.2020.03.017

  • Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Fu Binsheng, E-mail:fubinsh@mail.sysu.edu.cn
  • Received Date: 2020-01-28
    Available Online: 2021-01-19
  • Publish Date: 2020-05-15
    Abstract
  • Liver transplantation is the most effective means to treat the related end-stage liver disease caused by non-alcoholic fatty liver disease (NAFLD). But the recurrence rate of NAFLD after liver transplantation is very high due to the affection of obesity, metabolic syndrome and other adverse factors. In recent years, liver transplantation for NAFLD related end-stage liver disease has made some progress both in China and abroad. This article reviews the research progress of NAFLD and liver transplantation for NAFLD.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    DRESCHER HK, WEISKIRCHEN S, WEISKIRCHEN R. Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)[J]. Cells, 2019, 8(8): E845. DOI: 10.3390/cells8080845.
    [2]
    WONG VW, CHAN WK, CHITTURI S, et al. Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment[J]. J Gastroenterol Hepatol, 2018, 33(1):70-85. DOI: 10.1111/jgh.13857.
    [3]
    BHATI C, IDOWU MO, SANYAL AJ, et al. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis[J]. Transplantation, 2017, 101(8):1867-1874. DOI: 10.1097/TP.0000000000001709.
    [4]
    FAN JG, KIM SU, WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67(4):862-873. DOI: 10.1016/j.jhep.2017.06.003.
    [5]
    LI Z, XUE J, CHEN P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a Meta-analysis of published studies[J]. J Gastroenterol Hepatol, 2014, 29(1):42-51. DOI: 10.1111/jgh.12428.
    [6]
    CARTER D, DIETERICH DT, CHANG C. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in liver transplantation[J]. Clin Liver Dis, 2018, 22(1):213-227. DOI: 10.1016/j.cld.2017.08.015.
    [7]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84. DOI: 10.1002/hep.28431.
    [8]
    LIU K, MCCAUGHAN GW. Epidemiology and etiologic associations of non-alcoholic fatty liver disease and associated HCC[J]. Adv Exp Med Biol, 2018, 1061:3-18. DOI: 10.1007/978-981-10-8684-7_2.
    [9]
    CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases[J]. Hepatology, 2018, 67(1):328-357. DOI: 10.1002/hep.29367.
    [10]
    LEE SW, LEE TY, YANG SS, et al. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(2):176-180. doi: 10.1016/S1499-3872(16)60132-7
    [11]
    BEDOSSA P. Pathology of non-alcoholic fatty liver disease[J]. Liver Int, 2017, 37 (Suppl 1):85-89. DOI: 10.1111/liv.13301.
    [12]
    TANAKA N, KIMURA T, FUJIMORI N, et al. Current status, problems, and perspectives of non-alcoholic fatty liver disease research[J]. World J Gastroenterol, 2019, 25(2):163-177. DOI: 10.3748/wjg.v25.i2.163.
    [13]
    BZOWEJ NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation[J]. Curr Opin Organ Transplant, 2018, 23(2):169-174. DOI: 10.1097/MOT. 0000000000000502.
    [14]
    KERN B, FEURSTEIN B, FRITZ J, et al. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation[J]. Eur J Gastroenterol Hepatol, 2019, 31(2):205-210. DOI: 10.1097/MEG.0000000000001270.
    [15]
    LEWIN SM, MEHTA N, KELLEY RK, et al. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma[J]. Liver Transpl, 2017, 23(8):1015-1022. DOI: 10.1002/lt.24764.
    [16]
    YOUNOSSI ZM, LOOMBA R, RINELLA ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2018, 68(1):361-371. DOI: 10.1002/hep.29724.
    [17]
    CHITTURI S, WONG VW, CHAN WK, et al. The Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 2: management and special groups[J]. J Gastroenterol Hepatol, 2018, 33(1):86-98. DOI: 10.1111/jgh.13856.
    [18]
    ROMERO-GÓMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4):829-846. DOI: 10.1016/j.jhep.2017.05.016.
    [19]
    GELLI C, TAROCCHI M, ABENAVOLI L, et al. Effect of a counseling-supported treatment with the mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2017, 23(17):3150-3162. DOI: 10.3748/wjg.v23.i17.3150.
    [20]
    DONG F, ZHANG Y, HUANG Y, et al. Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial[J]. Sci Rep, 2016, 6:36783. DOI: 10.1038/srep36783.
    [21]
    CONZEN KD, VACHHARAJANI N, COLLINS KM, et al. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis[J]. HPB (Oxford), 2015, 17(3):251-257. DOI: 10.1111/hpb.12340.
    [22]
    TSOCHATZIS E, COILLY A, NADALIN S, et al. International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation[J]. Transplantation, 2019, 103(1): 45-56. DOI: 10.1097/TP.0000000000002433.
    [23]
    ESQUIVEL CM, GARCIA M, ARMANDO L, et al. Laparoscopic sleeve gastrectomy resolves NAFLD: another formal indication for bariatric surgery?[J]. Obes Surg, 2018, 28(12):4022-4033. DOI: 10.1007/s11695-018-3466-7.
    [24]
    PAIS R, BARRITT AS 4TH, CALMUS Y, et al. NAFLD and liver transplantation: current burden and expected challenges[J]. J Hepatol, 2016, 65(6):1245-1257. DOI: 10.1016/j.jhep.2016.07.033.
    [25]
    ALKHOURI N, HANOUNEH IA, ZEIN NN, et al. Liver transplantation for nonalcoholic steatohepatitis in young patients[J]. Transpl Int, 2016, 29(4):418-424. DOI: 10.1111/tri.12694.
    [26]
    SAAB S, LALEZARI D, PRUTHI P, et al. The impact of obesity on patient survival in liver transplant recipients: a Meta-analysis[J]. Liver Int, 2015, 35(1):164-170. DOI: 10.1111/liv.12431.
    [27]
    GERMANI G, LARYEA M, RUBBIA-BRANDT L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation[J]. Transplantation, 2019, 103(1):57-67. DOI: 10.1097/TP.0000000000002485.
    [28]
    PATEL YA, BERG CL, MOYLAN CA. Nonalcoholic fatty liver disease: key considerations before and after liver transplantation[J]. Dig Dis Sci, 2016, 61(5):1406-1416. DOI: 10.1007/s10620-016-4035-3.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (161) PDF downloads(11) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return